News & AnalysisEncellin fetches $5.9m seedEncellin, a personalized regenerative medicine biotech company, has secured $5.9 million in seed financing.ByIris Dorbian5 August 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs